List of Excipients in Branded Drug LEUKERAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Woodward Pharma Services LLC	LEUKERAN	chlorambucil	69784-610	ANHYDROUS LACTOSE
Woodward Pharma Services LLC	LEUKERAN	chlorambucil	69784-610	CELLULOSE, MICROCRYSTALLINE
Woodward Pharma Services LLC	LEUKERAN	chlorambucil	69784-610	FERRIC OXIDE RED
Woodward Pharma Services LLC	LEUKERAN	chlorambucil	69784-610	FERRIC OXIDE YELLOW
Woodward Pharma Services LLC	LEUKERAN	chlorambucil	69784-610	HYPROMELLOSES

Leukeran Excipient Strategy and Commercial Opportunities for Chlorambucil

Last updated: August 15, 2026

Leukeran is the branded oral tablet containing chlorambucil, an alkylating agent used primarily in chronic lymphocytic leukemia and selected lymphomas. The product’s commercial opportunity is not based on active-ingredient exclusivity. It is based on differentiated generic or reformulated chlorambucil products that improve dose flexibility, stability, excipient tolerability, supply reliability, and handling of a cytotoxic drug.

The most attractive strategy is a low-risk, immediate-release tablet that preserves chlorambucil’s established clinical profile while addressing excipient sensitivities, dose splitting, packaging, and global supply constraints. A liquid formulation or modified-release product could offer greater differentiation but would carry materially higher stability, bioequivalence, containment, and regulatory risk.

What excipients are used in Leukeran tablets?

Leukeran 2 mg tablets use a conventional solid oral formulation containing chlorambucil with carbohydrate, starch, coating, and processing excipients. Public product information identifies excipients including lactose, sucrose, potato starch, acacia, colloidal anhydrous silica, magnesium stearate, titanium dioxide, and coating-related materials, depending on the market and label version (DailyMed, 2024; Electronic Medicines Compendium, 2024).

Leukeran formulation profile

Component	Function	Commercial relevance
Chlorambucil	Active pharmaceutical ingredient	Cytotoxic alkylating agent; highly potent and chemically sensitive
Lactose	Diluent and tablet-body excipient	Creates a potential lactose-intolerance and excipient-labeling issue
Sucrose	Diluent, binder, and coating-related ingredient	Relevant to sugar-restricted patients and product perception
Potato starch	Disintegrant and binder	Supports immediate release
Acacia	Binder and film or tablet-body excipient	Can affect granulation and moisture behavior
Colloidal anhydrous silica	Glidant and moisture-control aid	Supports powder flow and manufacturing consistency
Magnesium stearate	Lubricant	Excess use can slow disintegration and dissolution
Titanium dioxide	Opacifier and coating pigment	Subject to changing international regulatory treatment
Film-coating materials	Protection, appearance, swallowability	May be redesigned without changing the active ingredient

The exact excipient list should be controlled by market-specific regulatory labeling. US, UK, European Union, and other national labels may differ in coating composition, colorants, and pharmaceutical-grade specifications.

What excipient risks affect chlorambucil product development?

Chlorambucil presents a more demanding formulation problem than a conventional low-potency tablet. The main risks are chemical instability, low-dose content uniformity, occupational exposure during manufacturing, and the need to demonstrate comparable dissolution and bioavailability.

Chemical and physical stability

Chlorambucil is sensitive to degradation under unsuitable temperature and moisture conditions. The FDA label instructs storage of Leukeran tablets under refrigerated conditions, generally 2°C to 8°C, and warns that tablets should remain refrigerated until use (FDA, 2023). A reformulated product that permits room-temperature storage would have substantial commercial value, but the claim would require robust long-term, accelerated, in-use, and transport stability data.

Excipient selection affects:

• Water activity and moisture uptake.
• Microenvironmental pH.
• Oxidative degradation.
• Tablet hardness and friability.
• Dissolution after refrigerated storage.
• Stability after removal from the original package.
• Compatibility with high-barrier blister or bottle systems.

A conservative formulation should avoid unnecessary liquid water, reactive reducing or oxidizing impurities, and excipients with variable moisture content. Excipients should be screened for peroxide levels, aldehydes, residual solvents, and elemental impurities.

Low-dose content uniformity

Each Leukeran tablet contains 2 mg of chlorambucil. The active ingredient therefore represents a small fraction of the tablet mass. Blend uniformity, segregation control, and assay precision are central development risks.

A direct-compression formulation could reduce processing steps, but a wet-granulation process may provide better content uniformity and flow control if the active ingredient has poor handling characteristics. Wet granulation would require careful assessment because water exposure may increase degradation risk.

Potential approaches include:

1. Ordered mixing of chlorambucil onto a carrier excipient.
2. Dry granulation or roller compaction.
3. Low-shear wet granulation using a nonaqueous or low-moisture process.
4. Spray-dried or co-processed excipient systems.
5. A protective intermediate containing a controlled concentration of chlorambucil.

The selected process must limit operator exposure and prevent cross-contamination with other products.

What excipient strategies could differentiate a generic Leukeran product?

A generic manufacturer does not need to replicate every excipient in the reference product. Under the FDA abbreviated new drug application pathway, the applicant must demonstrate pharmaceutical equivalence and bioequivalence, while inactive ingredients must satisfy applicable safety and regulatory requirements (FDA, 2024a).

Lactose-free formulation

A lactose-free tablet is the clearest excipient-based opportunity. Lactose can be replaced with:

• Microcrystalline cellulose.
• Mannitol.
• Dibasic calcium phosphate.
• Partially pregelatinized starch.
• Spray-dried mannitol or co-processed cellulose systems.

A lactose-free label could improve suitability for patients who avoid lactose and simplify positioning in markets where lactose-free medicines have commercial relevance. The replacement must not alter dissolution, tablet density, moisture behavior, or chlorambucil stability.

Mannitol may provide good mouthfeel and low hygroscopicity but can produce brittle tablets or a distinct cooling sensation. Microcrystalline cellulose supports compactibility but may increase tablet disintegration time if overused. Dibasic calcium phosphate is relatively moisture-resistant but can introduce density and compression differences.

Sugar-reduced or sucrose-free coating

A sucrose-free or low-sugar product could remove a legacy excipient and support hospital formulary positioning. Film coating with hypromellose, polyvinyl alcohol, polyethylene glycol, and a suitable opacifier could replace a sugar-based coating system.

This strategy has two advantages. It reduces dependence on a traditional coating process and can improve coating uniformity at small batch sizes. It also creates a cleaner excipient profile for institutional buyers.

Titanium-dioxide-free coating

Titanium dioxide remains permitted in some markets but has faced regulatory restrictions or heightened scrutiny in others. A titanium-dioxide-free coating using calcium carbonate, iron oxides, or an unpigmented film could simplify multinational registration.

The tradeoff is that color and opacity may change. For a cytotoxic medicine, a clearly identifiable tablet with robust light protection remains important. Any alternative pigment must be assessed for impurity profile, light transmission, and patient recognition.

Low-moisture formulation

A low-moisture formulation may improve chlorambucil stability. Candidate excipient systems include anhydrous lactose, low-moisture microcrystalline cellulose, mannitol, and dry starch-based disintegrants. The formulation should be paired with a high-barrier package rather than relying on excipients alone.

What packaging strategy is required for chlorambucil tablets?

Packaging is part of the excipient and stability strategy because the reference product requires refrigerated storage. A technically superior package could create more commercial value than a minor tablet-composition change.

Primary packaging options

Packaging system	Potential advantage	Principal limitation
High-barrier blister	Unit-dose protection; reduces handling and exposure	Higher packaging cost; requires specialized sealing
Cold-form aluminum blister	Strong moisture and light barrier	Less transparent; higher material cost
HDPE bottle with desiccant	Familiar and scalable	Repeated opening can increase moisture exposure
Unit-dose hospital blister	Supports pharmacy handling and administration	More complex supply chain
Child-resistant bottle	Retail and outpatient suitability	Does not solve stability alone

The package should be evaluated for moisture ingress, oxygen transmission, light protection, tablet recovery after refrigerated storage, and compatibility with cytotoxic handling procedures.

A unit-dose blister is commercially attractive for hospitals because it reduces tablet handling and supports medication accountability. A calendarized blister could also reduce dosing errors in regimens involving alternate-day or intermittent administration, although the regimen itself is individualized and must not be implied by packaging design.

When does Leukeran lose exclusivity?

Leukeran and chlorambucil are legacy products. The active ingredient has been used clinically for decades, and ordinary composition-of-matter patent exclusivity has expired. The principal commercial barriers are therefore regulatory approval, manufacturing controls, product quality, supply reliability, and physician or institutional purchasing preferences.

Orange Book and patent position

The FDA Orange Book is the authoritative source for US listed patents and regulatory exclusivity associated with approved drug products (FDA, 2024b). Leukeran’s commercial position is not comparable to a recently approved specialty product with active composition, formulation, or method-of-use patents. Any applicant assessing entry should verify the current Orange Book entry for the relevant NDA and reference-listed drug status before filing.

For a legacy chlorambucil tablet, the likely protection profile is:

Protection category	Commercial assessment
Composition-of-matter patent	Expired
Basic tablet formulation patent	No apparent durable barrier comparable to modern branded products
Method-of-use patent	Limited relevance for established leukemia and lymphoma uses
Pediatric exclusivity	Not expected to create a current material barrier
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not a current general barrier to chlorambucil tablet entry
Regulatory exclusivity	Must be assessed against the current FDA listing
Trade secrets	Manufacturing process, supplier qualification, and stability data may remain important

A Paragraph IV challenge would be relevant only if an unexpired Orange Book-listed patent covered the reference product. For a legacy Leukeran tablet, the greater risk is usually whether a proposed product can meet the reference product’s quality, stability, and bioequivalence requirements rather than whether a meaningful patent wall remains.

What regulatory pathway applies to a generic Leukeran tablet?

A conventional 2 mg immediate-release chlorambucil tablet would generally be pursued through an ANDA if the reference-listed drug and product-specific requirements support that pathway. The applicant would need to establish:

• Same active ingredient, strength, dosage form, route, and conditions of use.
• Pharmaceutical equivalence.
• Bioequivalence.
• Adequate chemistry, manufacturing, and controls data.
• Acceptable inactive ingredients.
• Container-closure and stability data.
• Appropriate cytotoxic manufacturing controls.

The FDA may require comparative dissolution profiles and may scrutinize formulation differences that could affect absorption or degradation. A liquid, modified-release, or substantially different dosage form may require a different regulatory strategy, potentially including a 505(b)(2) application rather than a standard ANDA.

What commercial opportunities exist for Leukeran excipient reformulation?

Generic substitution

The largest opportunity is a reliable generic or multisource chlorambucil tablet. Commercial success would depend on sustained supply, competitive pricing, and acceptance by hospital and specialty-pharmacy purchasers.

Key differentiators include:

• Lactose-free composition.
• Sucrose-free coating.
• Titanium-dioxide-free coating.
• Improved tablet hardness and reduced friability.
• Unit-dose packaging.
• Consistent refrigerated distribution.
• Global availability.
• Reduced stock-out risk.

Hospital and oncology-channel supply

Chlorambucil is used in oncology settings where procurement teams value supply continuity and handling controls. A supplier that can provide tamper-evident, unit-dose, high-barrier packaging may obtain institutional contracts even without patent exclusivity.

The product should be designed for pharmacy workflows. Packaging that minimizes tablet removal, protects against moisture, and provides clear lot traceability can support hospital adoption.

Geographic expansion

The principal geographic opportunity is in markets where chlorambucil is approved but supply is inconsistent or branded Leukeran is expensive. Registration requirements will vary, especially for:

• Excipient acceptability.
• Cold-chain documentation.
• Bioequivalence standards.
• Nitrosamine and elemental-impurity controls.
• Cytotoxic manufacturing.
• Local pharmacovigilance.
• Labeling and pediatric presentation requirements.

A single global formula may not be optimal. Titanium-dioxide-free and lactose-free versions can reduce the number of regional formulation changes, but each market may still require different labeling and packaging.

Reformulated liquid or dispersible product

A liquid formulation could address swallowing difficulty and pediatric or geriatric administration. It also offers a potential 505(b)(2) or equivalent reformulation opportunity. The technical hurdles are significant:

• Chlorambucil hydrolysis and oxidation.
• Preservative compatibility.
• Dose uniformity during storage.
• Adsorption to containers and dosing devices.
• Light sensitivity.
• In-use stability.
• Cytotoxic contamination control.
• Palatability and caregiver handling.

A ready-to-use liquid would have higher differentiation but also higher development cost and regulatory exposure. An extemporaneous oral suspension kit may be more practical, combining a protected chlorambucil component with a validated diluent and dosing device.

How strong is the patent estate for a new chlorambucil formulation?

The patent estate for the legacy tablet is likely weak relative to newer oncology products. Commercial protection would need to come from a narrowly drafted formulation, package, process, or use claim.

Potential patentable subject matter could include:

• A defined low-moisture excipient matrix.
• A stability-enhancing microenvironmental pH system.
• A specific high-barrier packaging configuration.
• A unit-dose cytotoxic handling system.
• A liquid formulation with demonstrated in-use stability.
• A dispersible tablet with controlled degradation.
• A manufacturing process that improves content uniformity while reducing operator exposure.

A patent directed only to replacing lactose with another conventional diluent would face a substantial obviousness risk. Stronger claims would require measured performance differences, such as a defined degradation threshold after long-term storage, improved dissolution after temperature excursions, or a reproducible reduction in content-uniformity variability.

Which companies could challenge or compete with Leukeran?

Competition is likely to come from generic manufacturers, specialty oncology suppliers, and regional pharmaceutical companies rather than biosimilar developers. Chlorambucil is a small molecule, so biosimilar risk does not apply.

Competitive factors include:

• Existing approved chlorambucil tablets.
• Ability to maintain refrigerated distribution.
• Cytotoxic API sourcing.
• Manufacturing containment.
• Registration in multiple jurisdictions.
• Hospital contract access.
• Product serialization and traceability.
• Capacity to support small but clinically necessary volumes.

The market may have limited volume but high supply sensitivity. A shortage or discontinuation can create short-term pricing and contracting opportunities, but long-term profitability depends on disciplined production economics.

What revenue exposure is associated with Leukeran?

Leukeran is a niche oncology product rather than a major global pharmaceutical franchise. Revenue exposure is concentrated in:

• Chronic lymphocytic leukemia.
• Certain non-Hodgkin lymphoma regimens.
• Older or medically appropriate patients receiving oral alkylating therapy.
• Markets where alternative targeted therapies are unavailable, unsuitable, or unaffordable.

Commercial demand can decline as targeted agents and chemoimmunotherapy displace older regimens. The product remains relevant where cost, access, comorbidity, or treatment strategy supports chlorambucil use.

A reformulated product should therefore target supply reliability and procurement value rather than assume large volume growth. The strongest business case is a focused specialty generic with differentiated handling, packaging, and excipient specifications.

Key Takeaways

• Leukeran contains chlorambucil 2 mg in a conventional immediate-release tablet.
• Public labeling identifies lactose, sucrose, potato starch, acacia, colloidal silica, magnesium stearate, titanium dioxide, and coating-related materials, subject to market-specific variation.
• Chlorambucil’s principal formulation risks are chemical instability, moisture sensitivity, low-dose content uniformity, and cytotoxic manufacturing exposure.
• A lactose-free, sucrose-free, low-moisture tablet is the most practical reformulation opportunity.
• High-barrier unit-dose blister packaging could provide greater commercial value than a minor excipient change.
• Composition-of-matter exclusivity is expired; current market barriers are regulatory, manufacturing, supply, and contracting barriers.
• A conventional generic would generally follow the ANDA pathway if the product-specific regulatory conditions support it.
• Liquid and dispersible formulations offer higher differentiation but materially greater stability and regulatory risk.
• Biosimilar competition is irrelevant because chlorambucil is a small molecule.
• The commercial opportunity is a reliable specialty generic, not a high-growth branded oncology franchise.

FAQs

Can chlorambucil tablets be formulated without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or co-processed excipients, subject to comparative dissolution, stability, and bioequivalence requirements.

Is a room-temperature chlorambucil tablet commercially valuable?

Yes. The reference product’s refrigerated storage requirement creates distribution cost and handling constraints. A room-temperature claim would require robust stability evidence and would need to be supported by an appropriate moisture- and light-barrier package.

Can a new coating create patent protection for chlorambucil?

Possibly, but a routine coating substitution would likely provide weak protection. A stronger patent position would require a defined coating and measurable stability, dissolution, or handling advantage.

Would a chlorambucil oral liquid qualify as a generic product?

Not necessarily. A substantially different dosage form may require a 505(b)(2) application or another national reformulation pathway rather than a conventional ANDA.

Does chlorambucil have biosimilar competition?

No. Chlorambucil is a chemically synthesized small molecule. Competitive products are generics or other small-molecule formulations, not biosimilars.

References

1. DailyMed. (2024). Leukeran: Chlorambucil tablet, film coated prescribing information. U.S. National Library of Medicine.

2. Electronic Medicines Compendium. (2024). Leukeran 2 mg film-coated tablets: Summary of product characteristics. Datapharm.

3. U.S. Food and Drug Administration. (2023). Leukeran (chlorambucil) tablets: Prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024a). Abbreviated new drug application (ANDA) process. FDA.

5. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.